Skip to content

Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study

A Prospective, Randomized, Controlled Clinical Study to Evaluate the Agreement and Reproducibility of Visibly Digital Acuity Product

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05026658
Enrollment
358
Registered
2021-08-30
Start date
2021-07-22
Completion date
2021-10-04
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digital Acuity Product

Brief summary

Visual acuity is the relative ability of the eye to resolve detail that is usually expressed as the reciprocal of the minimum angular separation in minutes of two lines just resolvable as separate and that forms in the average human eye an angle of one minute. Visibly Inc. has developed a method for determining a patient's visual acuity electronically via a web-based software system that can be self-administered wherever convenient. This method provides an efficient alternative for people to have immediate access to visual acuity measurements.

Detailed description

The Visibly Digital Acuity Product (VDAP) is a web-based, self-guided software application intended for use by adults, ages 22 to 40, at home, to evaluate visual acuity with or without correction. The standalone software application allows the user to interface with the software via a web browser on two internet-enabled devices: * A computer screen (the Display) which displays optotypes * A touchscreen mobile device (the Remote) which operates as a remote control and interface for the user to respond to prompts related to the optotypes appearing on the Display while standing 10 feet away The software allows users to view and respond to displayed optotypes and uses the responses to categorize a user's visual acuity into one of two buckets: * 20/25 or better * Worse than 20/25

Interventions

DEVICEVisibly Digital Acuity Product

The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences: 1. V1, E, V2 2. E, V1, V2 3. V2, E, V1 4. E, V2, V1 Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2. The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences.

Sponsors

Visibly
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* 1\. Be between 22 and 40 years (inclusive) of age at the time of consent 2. Be able and willing to provide written informed consent, attend all scheduled visits and comply with all study procedures

Exclusion criteria

* 1\. Have any of the following conditions (based on subject report): 1. Advanced eye disease in either eye; 2. Poor vision as a result of refractive surgery in either eye; 3. Unable to walk; 4. Unable to hear or follow audio instructions.

Design outcomes

Primary

MeasureTime frameDescription
EffectivenessUp to 3 hoursThe proportion of study eyes with VDAP VA of 20/25 or better 20/25 or better \[Positive Predictive Value (PPV)\]
ReproducibilityUp to 3 hoursThe proportion of study eyes which receive the same VA classification (20/25 or Better vs. Worse than 20/25) for the two VDAP tests

Secondary

MeasureTime frameDescription
EffectivenessUp to 3 hoursThe proportion of subjects with matching VDAP and ETDRS VA classifications (20/25 or Better vs. Worse than 20/25) for both eyes (study eye and non-study eye)
ReproducibilityUp to 3 hoursThe proportion of subjects with matching VDAP VA classifications (20/25 or Better vs. Worse than 20/25) for the two VDAP tests for both eyes (study eye and non-study eye)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026